Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 ACIST Medical ... market leader of advanced imaging modalities for cardiology, showcased ... in two live cases at the Transcatheter Cardiovascular Therapeutics ... cases were presented from Medstar Washington Hospital Center ( ... University Medical Center ( New York, NY ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Mich., Oct. 19, 2011 Perrigo Company (Nasdaq: PRGO;TASE) ... agreement with Founder Pharma Co., Ltd., a wholly owned ... (SZSE: 000788).  Perrigo will supply infant formula manufactured in ... Pharma in China. Perrigo Chairman and CEO ...
... N.Y., Oct. 19, 2011  CureFAKtor Pharmaceuticals, LLC, a privately-held ... Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today ... will present a company overview at the Biotechnology Industry ... San Francisco, CA on Wednesday, October 26 at 9:00 ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Founder Group 2CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum 2
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Boston ... to create a monthly concert series, introducing young ... From the Top, America’s premier national platform celebrating ... musicians. Many of the young musicians featured will ... , “Boston Children’s Museum is fortunate to partner ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... New York City Department of,Health recently released a study ... obesity increased 17% over a two year period. With ... that they are,drinking sugar sweetened drinks with many calories, ... by drinking TrimWater, (http://www.trimwater.com )., TrimWater is a ...
... 29, 2008) Pauletta and Denzel Washington will present ... High School in Denzels hometown of Mount Vernon, N.Y. ... Pauletta and Denzel Washington Family Scholar in Neuroscience Awards ... of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles. ...
... of Queensland-based Astute Nanotechnology will celebrate the,achievements ... a special presentation and cocktail,reception tomorrow Tuesday, ... for industry partners to access the,expertise and ... of Excellence for Functional,Nanomaterials (ARC CFN). , ...
... 30 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc., (JPI), the Company engages in the ... supplement, and cosmetic products., AMDL today ...
... Psychemedics,Corporation (Amex: PMD ) today announced first ... The Company also announced a quarterly,dividend of $0.17 per ... 6,2008 to be paid on June 20, 2008. This ... Company,s revenue for the quarter ended March 31, 2008 ...
... Anthem,s Care Comparison Tool Gives Members in Wisconsin the ... Picture of Costs Associated with Medical Procedures, ... Blue Shield,in Wisconsin announced today the launch of its ... now nearly 3 million Anthem Blue Cross and Blue ...
Cached Medicine News:Health News:Time for New Yorkers to Drink Low-Calorie, Low-Sugar Flavored Water, TrimWater 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 3Health News:Astute Nanotechnology celebrates first year of success 2Health News:Astute Nanotechnology celebrates first year of success 3Health News:AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line 2Health News:Psychemedics Corporation Announces First Quarter Results 2Health News:Psychemedics Corporation Announces First Quarter Results 3Health News:Psychemedics Corporation Announces First Quarter Results 4Health News:Psychemedics Corporation Announces First Quarter Results 5Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 2Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 3
Plus cylinders only trial lens set....
This is a reduced form of the 100 Hue test and is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score. Kit includes 100 score pads....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Medicine Products: